Circulating Extracellular Vesicles: An Effective Biomarker for Cancer Progression DOI Creative Commons

Madhura Chatterjee,

Saurabh Gupta,

Sayoni Nag

et al.

Frontiers in Bioscience-Landmark, Journal Year: 2024, Volume and Issue: 29(11)

Published: Oct. 31, 2024

Extracellular vesicles (EVs), the ubiquitous part of human biology, represent a small heterogenous, membrane-enclosed body that contains diverse payload including genetic materials in form DNA, RNAs, non-coding etc. mostly mirroring their source origin. Since, vast majority research has been conducted on how nucleic acids, proteins, lipids, and metabolites, associated with EVs can be effectively utilized to identify disease progression therapeutic responses cancer patients, are increasingly being touted as valuable reliable identifiers biomarkers liquid biopsies. However, lack comprehensive clinical validation effective standardization protocols severely limits its applications beyond laboratories. The present review focuses understanding role circulating different cancers they could potentially treated biomarkers, typically due presence bioactive molecules such etc., utilization for fine-tuning therapies. Here, we provide brief general biology classification subsequently discuss circulatory EVs, affect level population.

Language: Английский

Exosome-based nanoparticles and cancer immunotherapy DOI Open Access
Jiarong Ye, Danni Li,

Yiting Jie

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 179, P. 117296 - 117296

Published: Aug. 20, 2024

Over the past decades, cancer immunotherapy has encountered challenges such as immunogenicity, inefficiency, and cytotoxicity. Consequently, exosome-based gained rapid traction a promising alternative. Exosomes, type of extracellular vesicles (EVs) ranging from 50 to 150 nm, are self-originating exhibit fewer side effects compared traditional therapies. Exosome-based encompasses three significant areas: vaccination, co-inhibitory checkpoints, adoptive T-cell therapy. Each these fields leverages inherent advantages exosomes, demonstrating substantial potential for individualized tumor therapy precision medicine. This review aims elucidate reasons behind promise nanoparticles therapies by examining their characteristics summarizing latest research advancements in immunotherapy.

Language: Английский

Citations

13
Exosomes in review: A new frontier in CAR-T cell therapies DOI
Jiguang Wang,

Samuel J Schellenberg,

Athena Demeros

et al.

Neoplasia, Journal Year: 2025, Volume and Issue: 62, P. 101147 - 101147

Published: March 3, 2025

Language: Английский

Citations

1
MicroRNA-enriched exosome as dazzling dancer between cancer and immune cells DOI
Chou‐Yi Hsu, Abdulrahman T. Ahmed, Pooja Bansal

et al.

Journal of Physiology and Biochemistry, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 24, 2024

Language: Английский

Citations

7
T-cell Engaging Bispecific Outer Membrane Vesicles (BiTE-OMV) for Targeted Prostate Cancer Immunotherapy DOI
Josephine Kang, Kyumin Kim, Shaoqing Ju

et al.

Journal of Drug Delivery Science and Technology, Journal Year: 2025, Volume and Issue: 107, P. 106762 - 106762

Published: March 5, 2025

Language: Английский

Citations

1
Harnessing Extracellular Vesicles for Targeted Drug Delivery in Ovarian Cancer DOI Creative Commons
Jang‐Hyuk Yun,

Yoo Rim Noh,

Seongkyeong Yoo

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(4), P. 528 - 528

Published: April 17, 2025

Ovarian cancer remains one of the most lethal gynecologic malignancies, primarily due to late-stage diagnosis, high recurrence rates, and development chemoresistance. Although targeted therapies have improved patient outcomes, their efficacy is often limited by off-target toxicity acquired drug resistance. Extracellular vesicles (EVs), nanoscale naturally released cells, emerged as promising carriers for precision delivery. This review provides a comprehensive overview recent advances in EV-based therapeutic strategies ovarian cancer, including delivery chemotherapeutic agents, nucleic acid therapeutics, immunomodulatory molecules. We further explore innovative engineering approaches enhance targeting specificity, such surface modification, cell source selection, biomaterial integration, magnetic nanoparticle-assisted Key translational challenges bringing clinical application are also addressed. Collectively, these insights underscore transformative potential platforms advancing personalized treatment cancer.

Language: Английский

Citations

0
Extracellular vesicles as nature's nano carriers in cancer therapy: insights toward preclinical studies and clinical applications DOI Creative Commons
Xiaotong Wu,

Yuhua Meng,

Zhimeng Yao

et al.

Pharmacological Research, Journal Year: 2025, Volume and Issue: unknown, P. 107751 - 107751

Published: May 1, 2025

Extracellular vesicles (EVs), which are secreted by various cell types, hold significant potential for cancer therapy. However, there several challenges and difficulties that limit their application in clinical settings. This review, integrates the work of our team recent advancements this research field, discusses EV-based treatment strategies to guide application. The following discussed: 1) leveraging inherent properties EVs development treatments; 2) modifying using EV engineering methods improve drug loading delivery; 3) targeting key molecules tumor-derived (TDE) synthesis inhibit production; 4) clearing TDEs from tumor microenvironment. Additionally, on basis into vaccines bispecific antibodies, review elaborates enhance antitumor immunity via modifications can ability stability progress AI technology targeted delivery drugs. Although limited enhancing abilities, provides an in-depth discussion prior studies. Finally, summarizes use therapy highlights need be addressed.

Language: Английский

Citations

0
Progress of exosomes in regulating tumor metastasis by remodeling the pre-metastatic immune microenvironment DOI

Jiangning Xiang,

Yao Lin,

Shan Wang

et al.

Cellular Immunology, Journal Year: 2025, Volume and Issue: unknown, P. 104960 - 104960

Published: May 1, 2025

Language: Английский

Citations

0
CLDN18.2 CAR‐derived Extracellular Vesicle Immunotherapy Improves Outcome in Murine Pancreatic Cancer DOI Creative Commons
Qing Yue, Ke Jiang,

Hua Jiang

et al.

Advanced Healthcare Materials, Journal Year: 2025, Volume and Issue: unknown

Published: May 19, 2025

Abstract Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with no current effective treatment options. Chimeric antigen receptor (CAR) T cell therapy represents a powerful immunotherapeutic approach but faces major limitations in PDAC due to complex manufacturing and reduces efficacy within highly immunosuppressive tumor microenvironment (TME). Small extracellular vesicles (sEVs) derived from CAR‐T cells present novel strategy address these challenges. Here, CLDN18.2 are used generate CAR‐sEVs via ultracentrifugation. The purified exhibit typical sEV size morphology, containing established markers, carry functional CAR proteins along cytotoxic molecules such as granzyme B. In vitro, displays potent activity against murine + cells, whereas significant effects observed − non‐transformed cells. an aggressive orthotopic model, CAR‐sEV administration growth measured by bioluminescence imaging significantly extends survival. Notably, also prolong survival compared conventional CLDN18.2‐targeting further supporting their therapeutic potential. Moreover, unlike do not induce systemic IL‐6 release vivo. These findings position promising modality for PDAC, offering innovative potentially safer platform solid immunotherapy.

Language: Английский

Citations

0
Role of extracellular vesicles in cancer: implications in immunotherapeutic resistance DOI Creative Commons
S. Wang, Zerui Wang, Min Liu

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: May 22, 2025

Extracellular vesicles (EVs) are lipid membrane-bound involved in cell-cell communication, particularly the context of cancer. Immunotherapy, a rapidly evolving field oncology, is type cancer treatment relying on body's own immune system to fight mutated cells. Recently, significance immunotherapeutic resistance has been increasingly acknowledged owing heightened prevalence and its commonly advanced stage upon diagnosis. However, complexity heterogeneity tumor cells pose challenges immunotherapy, role EVs remains unclear. Recent studies focused as heterogeneous groups nanoparticles intercellular within microenvironment (TME). EVs, which include exosomes, shed microvesicles, while apoptotic bodies carry diverse range molecular cargo, including proteins, nucleic acids, lipids, other bioactive molecules. The versatility make them fascinating area study, with promising implications for future immunology medicine. This brief review highlights involvement (e.g., PD-L1 transfer, miRNA-mediated pathways) focus their biogenesis, secretion, functional roles cancer, underscoring potential diagnostic therapeutic tools.

Language: Английский

Citations

0
Circulating Extracellular Vesicles: An Effective Biomarker for Cancer Progression DOI Creative Commons

Madhura Chatterjee,

Saurabh Gupta,

Sayoni Nag

et al.

Frontiers in Bioscience-Landmark, Journal Year: 2024, Volume and Issue: 29(11)

Published: Oct. 31, 2024

Extracellular vesicles (EVs), the ubiquitous part of human biology, represent a small heterogenous, membrane-enclosed body that contains diverse payload including genetic materials in form DNA, RNAs, non-coding etc. mostly mirroring their source origin. Since, vast majority research has been conducted on how nucleic acids, proteins, lipids, and metabolites, associated with EVs can be effectively utilized to identify disease progression therapeutic responses cancer patients, are increasingly being touted as valuable reliable identifiers biomarkers liquid biopsies. However, lack comprehensive clinical validation effective standardization protocols severely limits its applications beyond laboratories. The present review focuses understanding role circulating different cancers they could potentially treated biomarkers, typically due presence bioactive molecules such etc., utilization for fine-tuning therapies. Here, we provide brief general biology classification subsequently discuss circulatory EVs, affect level population.

Language: Английский

Citations

1